EMA Authorised: Enjaymo (sutimlimab) — Recordati Rare Diseases

View source ↗

Summary

EMA authorised Enjaymo (sutimlimab) for the treatment of cold agglutinin disease (autoimmune hemolytic anemia), with orphan medicine designation; decision date …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autoimmune Hemolytic Anemia
• Cold Agglutinin Disease

Drugs mentioned

• Enjaymo (sutimlimab)

Snippet

Status: Authorised. Therapeutic area: Hemolysis;Anemia, Hemolytic, Autoimmune. MAH: Recordati Rare Diseases. Decision date: 01/08/2025. Orphan medicine